Skip to content 
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. more
| Time Frame | ALVO | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 5.08% | 1.64% | -0.4% |
| 1-Month Return | 7.48% | 2.13% | 0.14% |
| 3-Month Return | -36.56% | 8.39% | 2.61% |
| 6-Month Return | -43.56% | 16.16% | 8.7% |
| 1-Year Return | -60.59% | 9.86% | 13% |
| 3-Year Return | -56.66% | 17.8% | 72.1% |
| 5-Year Return | -52.61% | 33.74% | 79.31% |
| 10-Year Return | -46.97% | 135.48% | 268.2% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 66.62M | 36.77M | 83.03M | 91.43M | 489.68M | [{"date":"2020-12-31","value":13.6,"profit":true},{"date":"2021-12-31","value":7.51,"profit":true},{"date":"2022-12-31","value":16.96,"profit":true},{"date":"2023-12-31","value":18.67,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Cost of Revenue | - | - | 64.09M | 160.86M | 185.31M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":34.59,"profit":true},{"date":"2023-12-31","value":86.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Profit | 66.62M | 36.77M | 18.93M | (69.42M) | 304.37M | [{"date":"2020-12-31","value":21.89,"profit":true},{"date":"2021-12-31","value":12.08,"profit":true},{"date":"2022-12-31","value":6.22,"profit":true},{"date":"2023-12-31","value":-22.81,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Margin | 100.00% | 100.00% | 22.80% | (75.93%) | 62.16% | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":22.8,"profit":true},{"date":"2023-12-31","value":-75.93,"profit":false},{"date":"2024-12-31","value":62.16,"profit":true}] |
| Operating Expenses | 204.15M | 272.23M | 365.38M | 285.44M | 234.73M | [{"date":"2020-12-31","value":55.87,"profit":true},{"date":"2021-12-31","value":74.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.12,"profit":true},{"date":"2024-12-31","value":64.24,"profit":true}] |
| Operating Income | (137.54M) | (235.46M) | (346.44M) | (354.86M) | 69.64M | [{"date":"2020-12-31","value":-197.49,"profit":false},{"date":"2021-12-31","value":-338.09,"profit":false},{"date":"2022-12-31","value":-497.45,"profit":false},{"date":"2023-12-31","value":-509.53,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (254.75M) | (28.28M) | (295.73M) | (426.19M) | (440.19M) | [{"date":"2020-12-31","value":-25474600000,"profit":false},{"date":"2021-12-31","value":-2828000000,"profit":false},{"date":"2022-12-31","value":-29573100000,"profit":false},{"date":"2023-12-31","value":-42619000000,"profit":false},{"date":"2024-12-31","value":-44019100000,"profit":false}] |
| Pre-Tax Income | (291.77M) | (149.20M) | (551.65M) | (651.05M) | (217.56M) | [{"date":"2020-12-31","value":-29177000000,"profit":false},{"date":"2021-12-31","value":-14919800000,"profit":false},{"date":"2022-12-31","value":-55164700000,"profit":false},{"date":"2023-12-31","value":-65104900000,"profit":false},{"date":"2024-12-31","value":-21756300000,"profit":false}] |
| Income Taxes | (121.73M) | (47.69M) | (38.07M) | (99.32M) | 14.30M | [{"date":"2020-12-31","value":-851.17,"profit":false},{"date":"2021-12-31","value":-333.5,"profit":false},{"date":"2022-12-31","value":-266.18,"profit":false},{"date":"2023-12-31","value":-694.48,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Income After Taxes | (170.04M) | (101.50M) | (513.58M) | (551.73M) | (231.86M) | [{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false},{"date":"2024-12-31","value":-23186400000,"profit":false}] |
| Income From Continuous Operations | (170.04M) | (101.50M) | (513.58M) | (551.73M) | (231.86M) | [{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false},{"date":"2024-12-31","value":-23186400000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (170.04M) | (101.50M) | (513.58M) | (551.73M) | (231.86M) | [{"date":"2020-12-31","value":-17004400000,"profit":false},{"date":"2021-12-31","value":-10150400000,"profit":false},{"date":"2022-12-31","value":-51358000000,"profit":false},{"date":"2023-12-31","value":-55173100000,"profit":false},{"date":"2024-12-31","value":-23186400000,"profit":false}] |
| EPS (Diluted) | (0.30) | 0.13 | (5.53) | (3.42) | (1.33) | [{"date":"2020-12-31","value":-231.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4330.67,"profit":false},{"date":"2023-12-31","value":-2676.06,"profit":false},{"date":"2024-12-31","value":-1040.69,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| ALVO | |
|---|---|
| Cash Ratio | 0.14 |
| Current Ratio | 1.42 |
| Quick Ratio | 0.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ALVO | |
|---|---|
| ROA (LTM) | 1.98% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| ALVO | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 1.13 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.13 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ALVO | |
|---|---|
| Trailing PE | 22.48 |
| Forward PE | 10.46 |
| P/S (TTM) | 2.81 |
| P/B | 0.00 |
| Price/FCF | NM |
| EV/R | 4.93 |
| EV/Ebitda | 24.99 |
Alvotech (ALVO) share price today is $5.26
Yes, Indians can buy shares of Alvotech (ALVO) on Vested. To buy
Yes, you can purchase fractional shares of Alvotech (ALVO) via the Vested app. You can start investing in Alvotech (ALVO) with a minimum investment of $1.
You can invest in shares of Alvotech (ALVO) via Vested in three simple steps:
The 52-week high price of Alvotech (ALVO) is $13.26. The 52-week low price of Alvotech (ALVO) is $4.32.
The price-to-earnings (P/E) ratio of Alvotech (ALVO) is 22.4783
The price-to-book (P/B) ratio of Alvotech (ALVO) is 0.00
The dividend yield of Alvotech (ALVO) is 0.00%
The market capitalization of Alvotech (ALVO) is $1.61B
The stock symbol (or ticker) of Alvotech is ALVO
Consider the share price of Alvotech as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Alvotech has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Alvotech shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Alvotech stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Alvotech and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Alvotech stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
